Mainz Biomed N.V. MYNZ 深 滬
等待開盤 01-29 09:30:00 美东时间
1.19
-0.030
-2.46%
華盛通- 最 高1.27
- 今 開1.20
- 成交量 16.79万股
- 最 低 1.15
- 昨 收 1.22
- 總市值 1021.48万
- 52周最高 8.1639
- 市盈率 靜 --
- 換手率 1.96%
- 52周最低 0.92
- 委 比 2.01%
- 總股本 858.39万
- 歷史最高 1200.00
- 量 比 0.19
- 振 幅 9.84%
- 歷史最低 0.92
- 每 手 1
- 風險率 1.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mainz Biomed NV Files Initial Statement of Beneficial Ownership for CFO William Caragol
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for CFO William Caragol Mainz Biomed NV has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists William J. Caragol as the beneficial owner in his role as Chief Financial
01-27 05:09
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for Director Heinrich Dreismann
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for Director Heinrich Dreismann Mainz Biomed NV has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Heinrich Dreismann as the beneficial owner in his capacity as Dire
01-27 05:06
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for Director Gregory J. Tibbitts
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for Director Gregory J. Tibbitts Mainz Biomed NV has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Gregory J. Tibbitts as the beneficial owner in his capacity as Di
01-27 05:04
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
Mainz Biomed will present its study on a blood-based mRNA signature combined with AI to differentiate PDAC from IPMN at the AACR 2026 meeting in San Diego, aiming to advance pancreatic cancer screening and reduce mortality.
01-14 14:15
Mainz Biomed Provides Review of 2025 Highlights
Mainz Biomed announced major achievements in 2025, including launching the eAArly DETECT 2 study for its next-generation colorectal cancer test and the feasibility study for a pancreatic cancer blood test showing 100% sensitivity and 95% specificity. ColoAlert®, their DNA-based CRC test, was registered in the UK and Switzerland, with partnerships expanding into South America and Switzerland. Additionally, the company secured public funding for it...
01-05 14:15
DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio
<p>Mainz Biomed的ColoAlert®结直肠癌DNA检测被德国数字健康平台DoctorBox纳入其服务组合，标志着公司在欧洲增长战略中的重要进展。通过与DoctorBox的合作，ColoAlert®在家即可使用，使早期检测更加便捷，降低了筛查障碍，强调了创新个性化预防医学的重要性。</p>
2025-12-02 13:01
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
Mainz Biomed and OncoVanguard8 have signed an MOU to introduce ColoAlert®, a DNA-based colorectal cancer screening test, to South America, starting with Peru. The collaboration aims to address the high prevalence of CRC in Peru, Colombia, and Ecuador, with an estimated 17,000 new cases annually. The rollout is expected to enhance early detection and align with public health initiatives. The MOU outlines commercial, legal, and regulatory terms for...
2025-11-18 13:01
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 208.1% to $27.33...
2025-11-13 20:06
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
Mainz Biomed, a molecular genetics diagnostic company, will participate in MEDICA 2025, a leading global healthcare trade show in Düsseldorf, Germany. The Company will showcase its ColoAlert®, a non-invasive test for early colorectal cancer detection, and other diagnostic solutions. MEDICA attracts thousands of exhibitors and visitors, fostering innovation and collaboration in healthcare. Mainz Biomed aims to strengthen partnerships and raise awa...
2025-11-12 13:01
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
Mainz Biomed N.V. will participate in the 38th Annual GARPS conference in Germany to strengthen connections with gastroenterology experts, discuss cancer prevention, and showcase its ColoAlert® colorectal cancer detection product. The event offers opportunities for collaboration and education on early cancer detection. More information is available on the company’s website or via LinkedIn, X, and Facebook.
2025-11-10 13:01
